Rein Therapeutics Inc (RNTX) — Cash Flow-to-Debt Ratio
Rein Therapeutics Inc (RNTX) has a Cash Flow-to-Debt Ratio of -0.23x as of March 2026, meaning its operating cash flow of $-3.42 Million could theoretically repay 0% of its total liabilities ($14.70 Million) in one year. Explore RNTX cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rein Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Rein Therapeutics Inc across 11 annual periods. Also explore balance sheet size of Rein Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Rein Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Rein Therapeutics Inc. For market capitalisation and broader financial context, see Rein Therapeutics Inc (RNTX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.67x | $-19.36 Million | $7.24 Million | ▼ -78.1% |
| 2024 | -1.50x | $-22.29 Million | $14.85 Million | ▼ -651.3% |
| 2023 | -0.20x | $-19.81 Million | $99.12 Million | ▲ +97.3% |
| 2022 | -7.35x | $-24.86 Million | $3.38 Million | ▼ -41.6% |
| 2021 | -5.19x | $-23.75 Million | $4.58 Million | ▼ -5.9% |
| 2020 | -4.90x | $-20.48 Million | $4.18 Million | ▼ -92.9% |
| 2019 | -2.54x | $-26.47 Million | $10.43 Million | ▲ +2.6% |
| 2018 | -2.61x | $-27.93 Million | $10.71 Million | ▲ +37.9% |
| 2017 | -4.20x | $-20.53 Million | $4.89 Million | ▼ -3641.6% |
| 2016 | -0.11x | $-15.01 Million | $133.83 Million | ▲ +3.9% |
| 2015 | -0.12x | $-11.71 Million | $100.26 Million | — |